Enicepatide

COMBINATION_PRODUCT7 trials

Sponsors

Carmot Therapeutics, Inc., Hoffmann-La Roche

Conditions

Healthy ParticipantsObesityObesity or OverweightOverweightOverweight or ObeseType 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

RecruitingNCT07626515

Hoffmann-La RocheHealthy Participants

Start: 2026-07-02End: 2027-05-14Target: 36Updated: 2026-09-08

Phase 2

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

CompletedNCT06525935

Carmot Therapeutics, Inc.Obesity, Overweight

Start: 2024-08-16End: 2025-12-08Updated: 2026-04-17

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Active, not recruitingNCT06628362

Carmot Therapeutics, Inc.Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-11-21End: 2026-09-24Updated: 2026-06-24

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Not yet recruitingNCT07589686

Hoffmann-La RocheObesity or Overweight

Start: 2026-09-30End: 2028-01-31Target: 486Updated: 2026-09-09

Phase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

RecruitingNCT07351045

Hoffmann-La RocheObesity or Overweight

Start: 2026-03-16End: 2028-08-28Target: 2000Updated: 2026-09-14

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

RecruitingNCT07351058

Hoffmann-La RocheObesity or Overweight, Type 2 Diabetes Mellitus

Start: 2026-03-23End: 2028-08-07Target: 1600Updated: 2026-09-14

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

RecruitingNCT07670416

Hoffmann-La RocheObesity, Overweight, Type 2 Diabetes Mellitus (T2DM)

Start: 2026-07-03End: 2028-03-15Target: 300Updated: 2026-09-10

Related Papers

2813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study

Diabetes2026-06-05

763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes

Diabetes2025-06-131 citations